FDA Approves AstraZeneca's Imfinzi-BCG Combination for High-Risk NMIBC

Key Takeaways

• DailyMed lists Imfinzi plus BCG for adults with BCG-naïve, high-risk NMIBC.
• POTOMAC (NCT03528694) enrolled 1,018 patients after TURBT; DFS HR was 0.68 versus BCG alone.
• Median DFS follow-up exceeded five years (60.7 months); median DFS was not reached in either arm at that cut.
• The regimen is not a BCG-unresponsive indication; that remains a separate clinical and regulatory lane.

What does the Imfinzi label now say?

According to the DailyMed U.S. Prescribing Information for Imfinzi, durvalumab plus BCG is indicated for BCG-naïve, high-risk NMIBC in adults.

High-risk disease in POTOMAC included T1, Grade 3/high-grade, CIS, or multiple/recurrent/large tumors. BCG-naïve meant no prior BCG or last BCG more than three years before entry.

How strong was the POTOMAC disease-free survival result?

AstraZeneca’s October 2025 Business Wire readout reported a DFS hazard ratio of 0.68 (95% CI 0.50–0.93; P=0.0154) for Imfinzi plus BCG induction and maintenance versus BCG alone.

• 32% relative risk reduction for high-risk recurrence, progression, or death
• Median follow-up 60.7 months
• Estimated median DFS not yet reached in either arm
• Benefit described as early and sustained from under four months after start

The Lancet final analysis and ESMO 2025 presentation supply the peer-reviewed backbone for that claim.

How was POTOMAC designed?

ClinicalTrials.gov NCT03528694 describes a global, randomized, open-label Phase III study of durvalumab plus BCG versus BCG alone in high-risk, BCG-naïve NMIBC.

Patients were randomized 1:1:1 to Imfinzi plus BCG induction and maintenance, Imfinzi plus BCG induction only, or BCG induction and maintenance. The approved story centers on the induction-plus-maintenance combination arm versus BCG control. Durvalumab ran for 13 cycles every four weeks (about one year).

Why NMIBC still needs better options

NCI’s bladder cancer treatment PDQ notes TURBT plus intravesical therapy, including BCG, as core care for non-muscle-invasive disease. Recurrence and progression still drive cystectomy risk.

Adding a systemic PD-L1 antibody for a year raises cost, infusion burden, and immune-related adverse events. Payers will weigh DFS gain against that load in BCG-eligible patients.

What should EU BD teams watch next?

U.S. labeling does not automatically mean EMA or NICE access. Watch CHMP opinion timing, BCG product mix in Europe, and how induction-only Imfinzi arms performed versus control.

Competitive readouts in BCG-naïve NMIBC, including other PD-1 combinations, will set pricing and share expectations. NIAGARA already put Imfinzi into muscle-invasive perioperative care; POTOMAC extends the franchise earlier.

Hospital formulary committees will also ask which BCG strain was used. DailyMed notes 24% of POTOMAC patients received TICE BCG and 76% received other BCG products. Local supply contracts may not match that mix.

Field medical teams need clean answers on immune-related adverse events when systemic PD-L1 blockade is layered onto intravesical BCG for a full year of combination therapy.

What remains unproven?

Overall survival superiority was not the primary win story in public POTOMAC summaries. Long-term cystectomy rates and real-world BCG supply constraints still matter.

Do not apply this label to BCG-unresponsive NMIBC. That setting has separate FDA development guidance and distinct approved agents. Confirm dosing, BCG brand use, and monitoring in the current Prescribing Information before launch planning.

Related NovaPharma coverage

• ESMO 2025 NMIBC highlights
• Prior Imfinzi bladder cancer approval coverage
• NICE Imfinzi stomach cancer update

Frequently Asked Questions

Primary Sources

1. DailyMed — Imfinzi Prescribing Information (NMIBC + BCG)
2. ClinicalTrials.gov NCT03528694 — POTOMAC
3. Business Wire — POTOMAC 32% DFS risk reduction
4. The Lancet — POTOMAC final analysis
5. NCI Cancer.gov — Bladder cancer treatment PDQ